SH2B3 (SH2B adapter protein 3) variants and mutations
SH2B3 (also known as SH2B adapter protein 3) is a human protein-coding gene encoding a SH2B adapter protein 3 protein. It restrains cytokine and growth-factor signaling in hematopoietic cells, including JAK-STAT pathways controlling blood-cell production. Loss-of-function variants can increase blood-cell proliferation and predispose to myeloproliferative neoplasms, while common variants influence autoimmune and hematologic traits. This analysis covers 1,356 SH2B3 variants and mutations. Of these, 98% have computational variant effect predictions. Disease context includes celiac disease, type 1 diabetes mellitus, and hypertensive disorder. Example SH2B3 variants include M1V, N2K, and N2D.
Variant analysis overview
- Gene: SH2B3
- Protein: SH2B adapter protein 3
- UniProt accession: Q9UQQ2
- Organism: Homo sapiens
- Variants analyzed: 1356
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 880 unspecified-consequence records; 291 missense variants; 123 synonymous variants; 37 frameshift variants; 5 in-frame deletions; 18 stop-gained variants; 2 in-frame insertions
- Prediction scores: 1,330 variants have prediction scores (98% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: celiac disease, type 1 diabetes mellitus, hypertensive disorder, coronary artery disorder, hypothyroidism, myocardial infarction, ischemic stroke, Abnormality of the skeletal system, myeloproliferative disorder, rheumatoid arthritis, myocardial ischemia, cardiovascular disorder.
Protein structure and variant hotspots
- Protein features: 2 domains; 5 post-translational modification sites.
- Structural context: 313 variants have structural context.
- PTM context: 19 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable SH2B3 variants
Examples include M1V, N2K, N2D, N2S, N2N, G3R, G3W, G3V. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1V (p.Met1Val), rs376261237, ClinGen CA6789591, ClinVar RCV002250348, MetaLR 0.10, MetaSVM -0.98, Pathogenic, Primary familial polycythemia due to EPO receptor mutation
- N2K (p.Asn2Lys), ExAC rs759758469, TOPMed rs759758469, gnomAD rs759758469, REVEL 0.11, MetaLR 0.18
- N2D (p.Asn2Asp), gnomAD 12-111418149-A-G, REVEL 0.21, MetaLR 0.19
- N2S (p.Asn2Ser), gnomAD 12-111418150-A-G, REVEL 0.15, MetaLR 0.15
- N2N (p.Asn2Asn), rs759758469, gnomAD 12-111418151-C-T, CADD 0.39
- G3R (p.Gly3Arg), TOPMed rs1396230188, gnomAD rs1396230188, REVEL 0.30, MetaLR 0.33
- G3W (p.Gly3Trp), NCI-TCGA Cosmic COSV1003, REVEL 0.36, MetaLR 0.37, Variant assessed as somatic; moderate impact.
- G3V (p.Gly3Val), gnomAD 12-111418153-G-T, REVEL 0.30, MetaLR 0.29
- G3E (p.Gly3Glu), gnomAD 12-111418153-G-A, REVEL 0.12, MetaLR 0.13
- G3G (p.Gly3Gly), gnomAD 12-111418154-G-A, CADD 5.80
- P4T (p.Pro4Thr), ExAC rs767790633, TOPMed rs767790633, gnomAD rs767790633, REVEL 0.08, MetaLR 0.09
- P4S (p.Pro4Ser), gnomAD 12-111418155-C-T, REVEL 0.10, MetaLR 0.09
- P4L (p.Pro4Leu), gnomAD 12-111418156-C-T, REVEL 0.06, MetaLR 0.08
- P4H (p.Pro4His), gnomAD 12-111418156-C-A, REVEL 0.08, MetaLR 0.08
- P4P (p.Pro4Pro), rs371451229, gnomAD 12-111418157-T-C, CADD 6.57
- A5T (p.Ala5Thr), Ensembl rs1052050655, MetaLR 0.03, MetaSVM -0.97
- A5V (p.Ala5Val), rs752520582, NCI-TCGA Cosmic COSV1003, ExAC rs752520582, gnomAD rs752520582, REVEL 0.08, MetaLR 0.07, Variant assessed as somatic; moderate impact.
- A5P (p.Ala5Pro), gnomAD 12-111418158-G-C, REVEL 0.05, MetaLR 0.05
- A5S (p.Ala5Ser), gnomAD 12-111418158-G-T, REVEL 0.04, MetaLR 0.06
- A5D (p.Ala5Asp), gnomAD 12-111418159-C-A, REVEL 0.09, MetaLR 0.07
- L6V (p.Leu6Val), ExAC rs760432654, gnomAD rs760432654, REVEL 0.03, MetaLR 0.03
- L6R (p.Leu6Arg), gnomAD 12-111418162-T-G, REVEL 0.12, MetaLR 0.06
- L6P (p.Leu6Pro), gnomAD 12-111418162-T-C, REVEL 0.07, MetaLR 0.05
- L6L (p.Leu6Leu), gnomAD 12-111418163-G-T, CADD 5.45
- Q7* (p.Gln7Ter), Ensembl rs1871217761, CADD 34.00
- Q7L (p.Gln7Leu), ExAC rs753744013, TOPMed rs753744013, MetaLR 0.11, MetaSVM -1.01
- Q7R (p.Gln7Arg), ExAC rs753744013, TOPMed rs753744013, REVEL 0.08, MetaLR 0.11
- Q7K (p.Gln7Lys), gnomAD 12-111418164-C-A, REVEL 0.09, MetaLR 0.09
- Q7E (p.Gln7Glu), gnomAD 12-111418164-C-G, REVEL 0.08, MetaLR 0.08
- Q7Q (p.Gln7Gln), gnomAD 12-111418166-G-A, CADD 6.12
- Q7H (p.Gln7His), gnomAD 12-111418166-G-T, REVEL 0.06, MetaLR 0.08
- P8R (p.Pro8Arg), TOPMed rs919771498, MetaLR 0.14, MetaSVM -0.89, Uncertain significance, Inborn genetic diseases
- P8A (p.Pro8Ala), rs1476262682, gnomAD 12-111418164-C-CA, CADD 23.50
- P8T (p.Pro8Thr), gnomAD 12-111418167-C-A, REVEL 0.09, MetaLR 0.11
- P8S (p.Pro8Ser), gnomAD 12-111418167-C-T, REVEL 0.05, MetaLR 0.09
- P8H (p.Pro8His), gnomAD 12-111418168-C-A, REVEL 0.17, MetaLR 0.17
- P8P (p.Pro8Pro), gnomAD 12-111418169-C-T, CADD 0.71
- S9A (p.Ser9Ala), TOPMed rs1223479715, gnomAD rs1223479715, REVEL 0.02, MetaLR 0.04, Uncertain significance, Inborn genetic diseases
- S9F (p.Ser9Phe), Ensembl rs2135546626, REVEL 0.07, MetaLR 0.10
- S9P (p.Ser9Pro), TOPMed rs1223479715, gnomAD rs1223479715, REVEL 0.04, MetaLR 0.07, Uncertain significance, Inborn genetic diseases
- S9T (p.Ser9Thr), gnomAD 12-111418170-T-A, REVEL 0.01, MetaLR 0.06
- S9C (p.Ser9Cys), gnomAD 12-111418171-C-G, REVEL 0.06, MetaLR 0.10
- S9Y (p.Ser9Tyr), gnomAD 12-111418171-C-A, REVEL 0.06, MetaLR 0.10
- S9S (p.Ser9Ser), gnomAD 12-111418172-C-G, CADD 6.03
- S10* (p.Ser10Ter), TOPMed rs1484288251, gnomAD rs1484288251, CADD 31.00
- S10A (p.Ser10Ala), Ensembl rs886242710, REVEL 0.01, MetaLR 0.06, Uncertain significance, Inborn genetic diseases
- S10L (p.Ser10Leu), TOPMed rs1484288251, gnomAD rs1484288251, REVEL 0.08, MetaLR 0.08, Uncertain significance, Inborn genetic diseases
- S10S (p.Ser10Ser), gnomAD 12-111418175-G-T, CADD 2.88
- P11L (p.Pro11Leu), gnomAD rs1201207431, REVEL 0.08, MetaLR 0.05, Uncertain significance, Inborn genetic diseases
- P11T (p.Pro11Thr), gnomAD 12-111418176-C-A, REVEL 0.05, MetaLR 0.02
- P11H (p.Pro11His), gnomAD 12-111418177-C-A, REVEL 0.08, MetaLR 0.05
- P11P (p.Pro11Pro), gnomAD 12-111418178-C-G, CADD 4.51
- S12F (p.Ser12Phe), TOPMed rs1261307883, gnomAD rs1261307883, REVEL 0.06, MetaLR 0.07
- S12P (p.Ser12Pro), gnomAD 12-111418179-T-C, REVEL 0.01, MetaLR 0.06
- S12A (p.Ser12Ala), gnomAD 12-111418179-T-G, REVEL 0.01, MetaLR 0.03
- S12Y (p.Ser12Tyr), gnomAD 12-111418180-C-A, REVEL 0.09, MetaLR 0.07
- S12S (p.Ser12Ser), gnomAD 12-111418181-T-C, CADD 4.42
- S13F (p.Ser13Phe), gnomAD rs774260657, REVEL 0.07, MetaLR 0.08
- S13P (p.Ser13Pro), Ensembl rs2135546707, REVEL 0.01, MetaLR 0.06, Uncertain significance, Inborn genetic diseases
- p.Ser13 Ser16del, rs1254306591, gnomAD 12-111418173-TCGC, CADD 13.40
- S13C (p.Ser13Cys), gnomAD 12-111418183-C-G, REVEL 0.04, MetaLR 0.09
- S13S (p.Ser13Ser), gnomAD 12-111418184-C-T, CADD 1.13
- A14T (p.Ala14Thr), Ensembl rs1004764255, REVEL 0.04, MetaLR 0.08, Uncertain significance, Inborn genetic diseases
- A14V (p.Ala14Val), ExAC rs201886863, TOPMed rs201886863, gnomAD rs201886863, REVEL 0.09, MetaLR 0.08
- A14Q (p.Ala14Gln), gnomAD 12-111418165-A-AG, CADD 22.90
- A14S (p.Ala14Ser), gnomAD 12-111418185-G-T, REVEL 0.04, MetaLR 0.05
- A14E (p.Ala14Glu), gnomAD 12-111418186-C-A, REVEL 0.08, MetaLR 0.09
- A14A (p.Ala14Ala), rs750025226, gnomAD 12-111418187-G-A, CADD 1.82
- P15L (p.Pro15Leu), ExAC rs758110085, TOPMed rs758110085, gnomAD rs758110085, REVEL 0.07, MetaLR 0.07, Uncertain significance, Inborn genetic diseases
- P15S (p.Pro15Ser), TOPMed rs1174249790, gnomAD rs1174249790, REVEL 0.03, MetaLR 0.04, Likely benign, Inborn genetic diseases
- P15P (p.Pro15Pro), gnomAD 12-111418190-C-A, CADD 4.91
- S16* (p.Ser16Ter), ExAC rs779622961, gnomAD rs779622961, CADD 32.00
- S16L (p.Ser16Leu), ExAC rs779622961, gnomAD rs779622961, REVEL 0.04, MetaLR 0.06, Uncertain significance, Inborn genetic diseases
- S16P (p.Ser16Pro), gnomAD 12-111418191-T-C, REVEL 0.02, MetaLR 0.05
- S16S (p.Ser16Ser), rs1213504614, gnomAD 12-111418193-A-G, CADD 1.65
- A17D (p.Ala17Asp), ExAC rs748515476, gnomAD rs748515476, REVEL 0.07, MetaLR 0.05
- A17P (p.Ala17Pro), TOPMed rs1871222094, REVEL 0.06, MetaLR 0.05, Uncertain significance, Inborn genetic diseases
- A17V (p.Ala17Val), ExAC rs748515476, gnomAD rs748515476, REVEL 0.03, MetaLR 0.06
- A17S (p.Ala17Ser), gnomAD 12-111418194-G-T, REVEL 0.01, MetaLR 0.04
- A17A (p.Ala17Ala), gnomAD 12-111418196-C-G, CADD 1.74
- S18Y (p.Ser18Tyr), TOPMed rs1382306616, gnomAD rs1382306616, REVEL 0.07, MetaLR 0.07, Uncertain significance, Inborn genetic diseases
- S18P (p.Ser18Pro), gnomAD 12-111418197-T-C, REVEL 0.01, MetaLR 0.04
- S18S (p.Ser18Ser), gnomAD 12-111418199-C-A, CADD 2.84
- P19A (p.Pro19Ala), Ensembl rs1871222725, MetaLR 0.06, MetaSVM -1.06
- P19L (p.Pro19Leu), 1000Genomes rs778291950, ExAC rs778291950, gnomAD rs778291950, REVEL 0.04, MetaLR 0.08
- P19Q (p.Pro19Gln), 1000Genomes rs778291950, ExAC rs778291950, gnomAD rs778291950, REVEL 0.03, MetaLR 0.07
- P19R (p.Pro19Arg), 1000Genomes rs778291950, ExAC rs778291950, gnomAD rs778291950, REVEL 0.03, MetaLR 0.08, Uncertain significance, Inborn genetic diseases
- P19T (p.Pro19Thr), gnomAD 12-111418200-C-A, REVEL 0.05, MetaLR 0.05
- P19P (p.Pro19Pro), rs770929984, gnomAD 12-111418202-G-A, CADD 2.48
- A20E (p.Ala20Glu), TOPMed rs1222585515, gnomAD rs1222585515, REVEL 0.02, MetaLR 0.05, Uncertain significance, Inborn genetic diseases
- A20T (p.Ala20Thr), TOPMed rs1871223364, REVEL 0.02, MetaLR 0.05, Uncertain significance, Inborn genetic diseases
- A20V (p.Ala20Val), TOPMed rs1222585515, gnomAD rs1222585515, REVEL 0.03, MetaLR 0.04, Uncertain significance, Inborn genetic diseases
- p.Ala20 Pro23del, gnomAD 12-111418197-TCCC, CADD 9.90
- A20A (p.Ala20Ala), rs774410594, gnomAD 12-111418205-G-A, CADD 1.99
- A21G (p.Ala21Gly), ExAC rs759666349, gnomAD rs759666349, MetaLR 0.11, MetaSVM -0.94
- A21T (p.Ala21Thr), gnomAD rs1299854240, REVEL 0.14, MetaLR 0.09
- A21V (p.Ala21Val), ExAC rs759666349, gnomAD rs759666349, REVEL 0.06, MetaLR 0.09
- A21S (p.Ala21Ser), gnomAD 12-111418206-G-T, REVEL 0.17, MetaLR 0.05
- A21E (p.Ala21Glu), gnomAD 12-111418207-C-A, REVEL 0.07, MetaLR 0.10
- A21A (p.Ala21Ala), rs772256437, gnomAD 12-111418208-G-A, CADD 3.21
- A22D (p.Ala22Asp), Ensembl rs2135546861, REVEL 0.02, MetaLR 0.05, Uncertain significance, Inborn genetic diseases
- A22G (p.Ala22Gly), Ensembl rs2135546861, Uncertain significance, Inborn genetic diseases
- A22P (p.Ala22Pro), ExAC rs775611726, gnomAD rs775611726, REVEL 0.06, MetaLR 0.02
- A22T (p.Ala22Thr), ExAC rs775611726, gnomAD rs775611726, REVEL 0.04, MetaLR 0.04, Uncertain significance, Inborn genetic diseases
- A22V (p.Ala22Val), Ensembl rs2135546861, MetaLR 0.03, MetaSVM -1.03
- A22S (p.Ala22Ser), gnomAD 12-111418209-G-T, REVEL 0.05, MetaLR 0.02
- A22A (p.Ala22Ala), gnomAD 12-111418211-C-A, CADD 5.33
- P23L (p.Pro23Leu), ExAC rs760472328, TOPMed rs760472328, gnomAD rs760472328, REVEL 0.06, MetaLR 0.08
- P23R (p.Pro23Arg), ExAC rs760472328, TOPMed rs760472328, gnomAD rs760472328, REVEL 0.08, MetaLR 0.14, Uncertain significance, Inborn genetic diseases
- P23Q (p.Pro23Gln), gnomAD 12-111418213-C-A, REVEL 0.09, MetaLR 0.16
- P23P (p.Pro23Pro), rs1435193343, gnomAD 12-111418214-G-A, CADD 3.09
- R24Q (p.Arg24Gln), rs1263604332, gnomAD rs1263604332, REVEL 0.12, MetaLR 0.08, Variant assessed as somatic; moderate impact.
- R24W (p.Arg24Trp), rs984848263, NCI-TCGA Cosmic COSV5798, TOPMed rs984848263, gnomAD rs984848263, REVEL 0.28, MetaLR 0.18, Uncertain significance, Inborn genetic diseases
- R24G (p.Arg24Gly), rs775477645, gnomAD 12-111418212-CCG-, CADD 22.30
- R24R (p.Arg24Arg), gnomAD 12-111418215-C-A, CADD 9.80
- R24L (p.Arg24Leu), gnomAD 12-111418216-G-T, REVEL 0.23, MetaLR 0.16
- G25D (p.Gly25Asp), TOPMed rs1871226981, gnomAD rs1871226981, REVEL 0.26, MetaLR 0.11, Uncertain significance, Inborn genetic diseases
- G25S (p.Gly25Ser), gnomAD rs1490131569, REVEL 0.23, MetaLR 0.17
- G25C (p.Gly25Cys), gnomAD 12-111418218-G-T, REVEL 0.51, MetaLR 0.20
- G25V (p.Gly25Val), gnomAD 12-111418219-G-T, REVEL 0.39, MetaLR 0.18
- G25G (p.Gly25Gly), gnomAD 12-111418220-C-A, CADD 11.80
- W26* (p.Trp26Ter), TOPMed rs1189359287, gnomAD rs1189359287, CADD 37.00
- W26C (p.Trp26Cys), TOPMed rs1189359287, gnomAD rs1189359287, REVEL 0.86, MetaLR 0.74
- W26R (p.Trp26Arg), gnomAD 12-111418221-T-C, REVEL 0.78, MetaLR 0.71
- W26L (p.Trp26Leu), gnomAD 12-111418222-G-T, REVEL 0.78, MetaLR 0.73
- S27G (p.Ser27Gly), Ensembl rs2135546943, MetaLR 0.10, MetaSVM -1.02
- S27V (p.Ser27Val), gnomAD 12-111418223-GAGC, CADD 29.40
- S27C (p.Ser27Cys), gnomAD 12-111418224-A-T, REVEL 0.20, MetaLR 0.15
- S27I (p.Ser27Ile), gnomAD 12-111418225-G-T, REVEL 0.18, MetaLR 0.11
- S27R (p.Ser27Arg), gnomAD 12-111418226-C-G, REVEL 0.06, MetaLR 0.03
- S27S (p.Ser27Ser), rs1269390404, gnomAD 12-111418226-C-T, CADD 9.06
- E28K (p.Glu28Lys), NCI-TCGA Cosmic COSV5798, MetaLR 0.29, MetaSVM -0.37, Variant assessed as somatic; moderate impact.
- E28Q (p.Glu28Gln), gnomAD rs1433759305, REVEL 0.31, MetaLR 0.26
- E28* (p.Glu28Ter), gnomAD 12-111418227-G-T, CADD 37.00
- E28E (p.Glu28Glu), rs1180458317, gnomAD 12-111418229-G-A, CADD 8.61
- F29L (p.Phe29Leu), gnomAD rs1361601702, REVEL 0.84, MetaLR 0.53
- F29V (p.Phe29Val), TOPMed rs1871228675, MetaLR 0.56, MetaSVM 0.21
- C30G (p.Cys30Gly), gnomAD rs1421115167, REVEL 0.93, MetaLR 0.69
- C30S (p.Cys30Ser), TOPMed rs1871229237, MetaLR 0.69, MetaSVM 0.51, Uncertain significance, Inborn genetic diseases
- C30Y (p.Cys30Tyr), rs1871229237, ClinGen CA386717841, ClinVar RCV003120366, TOPMed rs1871229237, REVEL 0.89, MetaLR 0.71, Uncertain significance, Familial myelofibrosis
- C30* (p.Cys30Ter), gnomAD 12-111418232-CTG-, CADD 28.30
- C30R (p.Cys30Arg), gnomAD 12-111418233-T-C, REVEL 0.92, MetaLR 0.69
- C30W (p.Cys30Trp), gnomAD 12-111418235-T-G, REVEL 0.73, MetaLR 0.65
- E31D (p.Glu31Asp), TOPMed rs1871229645, REVEL 0.38, MetaLR 0.31
- E31G (p.Glu31Gly), Ensembl rs2135546995, REVEL 0.69, MetaLR 0.36
- E31* (p.Glu31Ter), gnomAD 12-111418236-G-T, CADD 36.00
- E31E (p.Glu31Glu), gnomAD 12-111418238-G-A, CADD 7.12
- L32F (p.Leu32Phe), TOPMed rs1361522871, gnomAD rs1361522871, REVEL 0.28, MetaLR 0.18
- L32V (p.Leu32Val), Ensembl rs2135547006, MetaLR 0.18, MetaSVM -0.86
- L32L (p.Leu32Leu), gnomAD 12-111418239-T-C, CADD 8.69
- H33L (p.His33Leu), ExAC rs765323352, gnomAD rs765323352, REVEL 0.85, MetaLR 0.65, Uncertain significance, Inborn genetic diseases
- H33N (p.His33Asn), ExAC rs761842617, gnomAD rs761842617, REVEL 0.84, MetaLR 0.66, Uncertain significance, Inborn genetic diseases
- H33Q (p.His33Gln), TOPMed rs976292388, gnomAD rs976292388, REVEL 0.72, MetaLR 0.60
- H33R (p.His33Arg), ExAC rs765323352, gnomAD rs765323352, REVEL 0.88, MetaLR 0.65, Uncertain significance, Inborn genetic diseases
- H33Y (p.His33Tyr), ExAC rs761842617, gnomAD rs761842617, REVEL 0.87, MetaLR 0.66, Uncertain significance, Inborn genetic diseases
- H33H (p.His33His), rs976292388, gnomAD 12-111418244-C-T, CADD 5.20
- A34D (p.Ala34Asp), gnomAD rs1871231182, REVEL 0.81, MetaLR 0.57
- A34T (p.Ala34Thr), Ensembl rs2135547061, REVEL 0.75, MetaLR 0.57
- p.Ala34dup, gnomAD 12-111418243-A-AC, CADD 17.00
- A34V (p.Ala34Val), gnomAD 12-111418246-C-T, REVEL 0.73, MetaLR 0.57
- A34A (p.Ala34Ala), rs749931559, gnomAD 12-111418247-C-A, CADD 0.28
- V35A (p.Val35Ala), Ensembl rs1871231900, REVEL 0.06, MetaLR 0.03, Uncertain significance, Inborn genetic diseases
- V35G (p.Val35Gly), Ensembl rs1871231900, REVEL 0.05, MetaLR 0.06, Uncertain significance
- V35I (p.Val35Ile), ExAC rs758024019, TOPMed rs758024019, gnomAD rs758024019, REVEL 0.12, MetaLR 0.03, Uncertain significance, Inborn genetic diseases
- V35L (p.Val35Leu), rs758024019, ClinGen CA386717871, ClinVar RCV002855993, REVEL 0.10, MetaLR 0.05, Uncertain significance, Inborn genetic diseases
- A36E (p.Ala36Glu), 1000Genomes rs574829930, ExAC rs574829930, TOPMed rs574829930, gnomAD rs574829930, REVEL 0.42, MetaLR 0.29
- A36V (p.Ala36Val), 1000Genomes rs574829930, ExAC rs574829930, TOPMed rs574829930, gnomAD rs574829930, REVEL 0.24, MetaLR 0.24
- A36T (p.Ala36Thr), gnomAD 12-111418251-G-A, REVEL 0.19, MetaLR 0.16
- A36A (p.Ala36Ala), gnomAD 12-111418253-G-T, CADD 0.71
- A37V (p.Ala37Val), rs1242525317, TOPMed rs1242525317, gnomAD rs1242525317, REVEL 0.21, MetaLR 0.13, Uncertain significance, Inborn genetic diseases
- A37T (p.Ala37Thr), gnomAD 12-111418254-G-A, REVEL 0.04, MetaLR 0.05
- A37A (p.Ala37Ala), rs756441267, gnomAD 12-111418256-G-C, CADD 5.96
- A38D (p.Ala38Asp), Ensembl rs2135547124, REVEL 0.73, MetaLR 0.43, Uncertain significance, Inborn genetic diseases
- A38G (p.Ala38Gly), Ensembl rs2135547124, MetaLR 0.43, MetaSVM -0.03
- A38T (p.Ala38Thr), rs2135547121, ClinGen CA386717885, ClinVar RCV002246834, Ensembl rs2135547121, REVEL 0.57, MetaLR 0.43, Benign, not specified
- A38del (p.Ala38del), gnomAD 12-111418250-AGCG, CADD 14.20
- A38V (p.Ala38Val), gnomAD 12-111418258-C-T, REVEL 0.60, MetaLR 0.43
- R39G (p.Arg39Gly), TOPMed rs933970612, gnomAD rs933970612, REVEL 0.21, MetaLR 0.12, Uncertain significance, Inborn genetic diseases
- R39P (p.Arg39Pro), ExAC rs778004604, TOPMed rs778004604, gnomAD rs778004604, REVEL 0.24, MetaLR 0.13, Uncertain significance
- R39Q (p.Arg39Gln), rs778004604, NCI-TCGA Cosmic COSV5798, ExAC rs778004604, TOPMed rs778004604, REVEL 0.10, MetaLR 0.10, Uncertain significance, Inborn genetic diseases; not provided
Public SH2B3 analysis runs
- SH2B3 analysis run — SH2B3 (1,356 variants) — completed 2026-08-19